Encompass Health's (EHC) Q3 results benefit from an increase in patient volumes and net patient revenue per discharge. Management currently projects adjusted EPS to be within $3.41-$3.52 for 2023.
While the top- and bottom-line numbers for Encompass Health (EHC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metri
Encompass Health's (EHC) Q3 results are likely to reflect improved inpatient volumes and bed additions, offset by higher operating expenses.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.
Here is how Encompass Health (EHC) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
The Rehabilitation Hospital of Columbus is Encompass Health's (EHC) sixth location in the state of Georgia.
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and RDNT are well-poised

5 Lucrative PEG-Based GARP Stocks for Investors

09:46am, Tuesday, 22'nd Aug 2023
Here are the five stocks that meet our screening criteria - PRDO, EHC, OSK, HSBC and PHM.
HURN, EHC, RDY, BOOM and HWKN are five stocks with explosive relative price strength.
Encompass Health Corporation has revised its growth outlook and capital investment spends for FY'23. EHC's growth strategy relies on building same-store revenues and adding new facilities to its portf
Encompass Health's (EHC) Q2 results reflect a growing patient base and improved net patient revenue per discharge. Management anticipates 2023 adjusted EPS within $3.31-$3.53, up from the earlier view
Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.
While the top- and bottom-line numbers for Encompass Health (EHC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics co
Encompass Health (EHC) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.89 per share a year ago.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE